Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012.
about
Multiple Drug Treatments That Increase cAMP Signaling Restore Long-Term Memory and Aberrant Signaling in Fragile X Syndrome Models.Synthesis and biological characterization of a series of novel diaryl amide M₁ antagonists.Octahydropyrrolo[3,4-c]pyrrole negative allosteric modulators of mGlu1.Synthesis and evaluation of 4,6-disubstituted pyrimidines as CNS penetrant pan-muscarinic antagonists with a novel chemotype.Molecular diversity of the three-component reaction of α-amino acids, dialkyl acetylenedicarboxylates and N-substituted maleimides.In silico studies targeting G-protein coupled receptors for drug research against Parkinson's disease.
P2860
Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Development of novel M1 antago ...... tion of the MLPCN probe ML012.
@en
type
label
Development of novel M1 antago ...... tion of the MLPCN probe ML012.
@en
prefLabel
Development of novel M1 antago ...... tion of the MLPCN probe ML012.
@en
P2093
P2860
P50
P1476
Development of novel M1 antago ...... tion of the MLPCN probe ML012.
@en
P2093
Bruce J Melancon
Christian Sevel
Douglas J Sheffler
J Scott Daniels
Margrith E Mattmann
Michael R Wood
Ryan D Morrison
Thomas J Utley
Thomas M Bridges
Yiu-Yin Cheung
P2860
P304
P356
10.1016/J.BMCL.2012.06.018
P407
P577
2012-06-15T00:00:00Z